From Wikipedia, the free encyclopedia
Thymopentin
Clinical data
Other namesL-arginyl-L-lysyl-L-α-aspartyl-L-valyl-L-tyrosine
ATC code
Identifiers
  • (3S)-3-[[(2S)-6-amino-2-[[(2S)-2-amino-5-(diaminomethylideneamino)pentanoyl]amino]hexanoyl]amino]-4-[[(2S)-1-[[(2S)-1-hydroxy-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-4-oxobutanoic acid
CAS Number
PubChem CID
ChemSpider
UNII
KEGG
ChEMBL
NIAID ChemDB
CompTox Dashboard ( EPA)
ECHA InfoCard 100.242.320 Edit this at Wikidata
Chemical and physical data
FormulaC30H49N9O9
Molar mass679.776 g·mol−1
3D model ( JSmol)
  • O=C(N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)O)Cc1ccc(O)cc1)C(C)C)CC(=O)O)CCCCN)[C@@H](N)CCC/N=C(\N)N
  • InChI=1S/C30H49N9O9/c1-16(2)24(28(46)38-22(29(47)48)14-17-8-10-18(40)11-9-17)39-27(45)21(15-23(41)42)37-26(44)20(7-3-4-12-31)36-25(43)19(32)6-5-13-35-30(33)34/h8-11,16,19-22,24,40H,3-7,12-15,31-32H2,1-2H3,(H,36,43)(H,37,44)(H,38,46)(H,39,45)(H,41,42)(H,47,48)(H4,33,34,35)/t19-,20-,21-,22-,24-/m0/s1 checkY
  • Key:PSWFFKRAVBDQEG-YGQNSOCVSA-N checkY
   (verify)

Thymopentin is an immunostimulant. As such, it has been used in several clinical studies in the early years of the AIDS pandemic (from 1983 to 1985). Thymopentin helped to improve immunological condition in several patients for a brief time under specific treatments. [1] [2] [3]

It interacts with T cells. [4]

It is a thymic polypeptide. [5]

References

  1. ^ Mascart-Lemone F, Huygen K, Clumeck N, Brenez D, Bolla K, Duchateau J (1983). "Stimulation of cellular function by thymopentin (TP-5) in three AIDS patients". Lancet. 322 (8352): 735–736. doi: 10.1016/S0140-6736(83)92271-7. PMID  6193382. S2CID  519367.
  2. ^ Clumeck N, Van de Perre P, Mascart-Lemone F, Cran S, Bolla K, Duchateau J (1984). "Preliminary results on clinical and immunological effects of thymopentin in AIDS". Int J Clin Pharmacol Res. 4 (6): 459–463. PMID  6398315.
  3. ^ Clumeck N, Cran S, Van de Perre P, Mascart-Lemone F, Duchateau J, Bolla K (1985). "Thymopentin treatment in AIDS and pre-AIDS patients". Surv Immunol Res. 4 (1): supp1 58–62. doi: 10.1007/BF02919057. PMID  3898293. S2CID  36555170.
  4. ^ Liu Z, Zheng X, Wang J, Wang E (2007). Egli M (ed.). "Molecular analysis of thymopentin binding to HLA-DR molecules". PLOS ONE. 2 (12): e1348. Bibcode: 2007PLoSO...2.1348L. doi: 10.1371/journal.pone.0001348. PMC  2137936. PMID  18159232. Open access icon
  5. ^ Peng Y, Chen Z, Yu W, et al. (July 2008). "Effects of thymic polypeptides on the thymopoiesis of mouse embryonic stem cells". Cell Biology International. 32 (10): 1265–71. doi: 10.1016/j.cellbi.2008.07.011. PMID  18692582. S2CID  24144448.


From Wikipedia, the free encyclopedia
Thymopentin
Clinical data
Other namesL-arginyl-L-lysyl-L-α-aspartyl-L-valyl-L-tyrosine
ATC code
Identifiers
  • (3S)-3-[[(2S)-6-amino-2-[[(2S)-2-amino-5-(diaminomethylideneamino)pentanoyl]amino]hexanoyl]amino]-4-[[(2S)-1-[[(2S)-1-hydroxy-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-4-oxobutanoic acid
CAS Number
PubChem CID
ChemSpider
UNII
KEGG
ChEMBL
NIAID ChemDB
CompTox Dashboard ( EPA)
ECHA InfoCard 100.242.320 Edit this at Wikidata
Chemical and physical data
FormulaC30H49N9O9
Molar mass679.776 g·mol−1
3D model ( JSmol)
  • O=C(N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)O)Cc1ccc(O)cc1)C(C)C)CC(=O)O)CCCCN)[C@@H](N)CCC/N=C(\N)N
  • InChI=1S/C30H49N9O9/c1-16(2)24(28(46)38-22(29(47)48)14-17-8-10-18(40)11-9-17)39-27(45)21(15-23(41)42)37-26(44)20(7-3-4-12-31)36-25(43)19(32)6-5-13-35-30(33)34/h8-11,16,19-22,24,40H,3-7,12-15,31-32H2,1-2H3,(H,36,43)(H,37,44)(H,38,46)(H,39,45)(H,41,42)(H,47,48)(H4,33,34,35)/t19-,20-,21-,22-,24-/m0/s1 checkY
  • Key:PSWFFKRAVBDQEG-YGQNSOCVSA-N checkY
   (verify)

Thymopentin is an immunostimulant. As such, it has been used in several clinical studies in the early years of the AIDS pandemic (from 1983 to 1985). Thymopentin helped to improve immunological condition in several patients for a brief time under specific treatments. [1] [2] [3]

It interacts with T cells. [4]

It is a thymic polypeptide. [5]

References

  1. ^ Mascart-Lemone F, Huygen K, Clumeck N, Brenez D, Bolla K, Duchateau J (1983). "Stimulation of cellular function by thymopentin (TP-5) in three AIDS patients". Lancet. 322 (8352): 735–736. doi: 10.1016/S0140-6736(83)92271-7. PMID  6193382. S2CID  519367.
  2. ^ Clumeck N, Van de Perre P, Mascart-Lemone F, Cran S, Bolla K, Duchateau J (1984). "Preliminary results on clinical and immunological effects of thymopentin in AIDS". Int J Clin Pharmacol Res. 4 (6): 459–463. PMID  6398315.
  3. ^ Clumeck N, Cran S, Van de Perre P, Mascart-Lemone F, Duchateau J, Bolla K (1985). "Thymopentin treatment in AIDS and pre-AIDS patients". Surv Immunol Res. 4 (1): supp1 58–62. doi: 10.1007/BF02919057. PMID  3898293. S2CID  36555170.
  4. ^ Liu Z, Zheng X, Wang J, Wang E (2007). Egli M (ed.). "Molecular analysis of thymopentin binding to HLA-DR molecules". PLOS ONE. 2 (12): e1348. Bibcode: 2007PLoSO...2.1348L. doi: 10.1371/journal.pone.0001348. PMC  2137936. PMID  18159232. Open access icon
  5. ^ Peng Y, Chen Z, Yu W, et al. (July 2008). "Effects of thymic polypeptides on the thymopoiesis of mouse embryonic stem cells". Cell Biology International. 32 (10): 1265–71. doi: 10.1016/j.cellbi.2008.07.011. PMID  18692582. S2CID  24144448.



Videos

Youtube | Vimeo | Bing

Websites

Google | Yahoo | Bing

Encyclopedia

Google | Yahoo | Bing

Facebook